Cargando…

Delivery is key: lessons learnt from developing splice‐switching antisense therapies

The use of splice‐switching antisense therapy is highly promising, with a wealth of pre‐clinical data and numerous clinical trials ongoing. Nevertheless, its potential to treat a variety of disorders has yet to be realized. The main obstacle impeding the clinical translation of this approach is the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godfrey, Caroline, Desviat, Lourdes R, Smedsrød, Bård, Piétri‐Rouxel, France, Denti, Michela A, Disterer, Petra, Lorain, Stéphanie, Nogales‐Gadea, Gisela, Sardone, Valentina, Anwar, Rayan, EL Andaloussi, Samir, Lehto, Taavi, Khoo, Bernard, Brolin, Camilla, van Roon‐Mom, Willeke MC, Goyenvalle, Aurélie, Aartsma‐Rus, Annemieke, Arechavala‐Gomeza, Virginia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412803/ https://www.ncbi.nlm.nih.gov/pubmed/28289078 http://dx.doi.org/10.15252/emmm.201607199

Ejemplares similares

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
por: Hammond, Suzan M, et al.
Publicado: (2021)

Splicing modulation therapy in the treatment of genetic diseases
por: Arechavala-Gomeza, Virginia, et al.
Publicado: (2014)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
por: Goyenvalle, Aurélie, et al.
Publicado: (2023)

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I
por: Koehorst, Emma, et al.
Publicado: (2020)

Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain
por: Zalachoras, Ioannis, et al.
Publicado: (2011)

An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I
por: López-Martínez, Andrea, et al.
Publicado: (2020)

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
por: Synofzik, Matthis, et al.
Publicado: (2022)

Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain
por: Zalachoras, Ioannis, et al.
Publicado: (2013)

Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
por: Evers, Melvin M., et al.
Publicado: (2011)

RFX1 and RFX3 Transcription Factors Interact with the D Sequence of Adeno-Associated Virus Inverted Terminal Repeat and Regulate AAV Transduction
por: Julien, Laura, et al.
Publicado: (2018)

Special Issue “Genetic Advances in Neuromuscular Disorders: From Gene Identification to Gene Therapy”
por: Arechavala-Gomeza, Virginia, et al.
Publicado: (2021)

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
por: Heinz, Annika, et al.
Publicado: (2021)

Researcher's Perceptions on Publishing “Negative” Results and Open Access
por: Echevarría, Lucía, et al.
Publicado: (2021)

Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics
por: Zhou, Haiyan, et al.
Publicado: (2023)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

Smad-binding decoy reduces extracellular matrix expression in human hypertrophic scar fibroblasts
por: Fan, Chen, et al.
Publicado: (2020)

Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies
por: Evers, Melvin M., et al.
Publicado: (2013)

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
por: Bizot, Flavien, et al.
Publicado: (2022)

Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice
por: Forand, Anne, et al.
Publicado: (2020)

Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2019)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
por: Toonen, Lodewijk J.A., et al.
Publicado: (2017)

Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review
por: Bakels, Hannah S., et al.
Publicado: (2021)

Novel viral vectors utilizing intron splice-switching to activate genome rescue, expression and replication in targeted cells
por: Viru, Liane, et al.
Publicado: (2011)

Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
por: Gustafsson, Oskar, et al.
Publicado: (2021)

Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
por: Toonen, Lodewijk J. A., et al.
Publicado: (2016)

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
por: Buijsen, Ronald A.M., et al.
Publicado: (2019)

Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription
por: Mollard, Amédée, et al.
Publicado: (2022)

Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA
por: Mastrokolias, Anastasios, et al.
Publicado: (2012)

Statistical method for modeling sequencing data from different technologies in longitudinal studies with application to Huntington disease
por: Fuady, Angga M., et al.
Publicado: (2020)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Exploring the Transcriptome of Ciliated Cells Using In Silico Dissection of Human Tissues
por: Ivliev, Alexander E., et al.
Publicado: (2012)

Osteopontin and phospho‐SMAD2/3 are associated with calcification of vessels in D‐CAA, an hereditary cerebral amyloid angiopathy
por: Grand Moursel, Laure, et al.
Publicado: (2019)

Therapeutic Strategies for Spinocerebellar Ataxia Type 1
por: Kerkhof, Laurie M. C., et al.
Publicado: (2023)

Correction: Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B
por: Krooss, Simon, et al.
Publicado: (2021)

Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
por: Soblechero‐Martín, Patricia, et al.
Publicado: (2021)

Cost-effective HRMA pre-sequence typing of clone libraries; application to phage display selection
por: Pepers, Barry A, et al.
Publicado: (2009)

Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
por: Toonen, Lodewijk J.A., et al.
Publicado: (2018)

Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias
por: Hommersom, Marina P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_medston2kdu77s5imsfrsh4lid